Abbott, AstraZeneca request FDA approval for cholesterol pill combo
2009-06-04 17:44:41 (GMT) (Caymanmama.com - Health News News)
Springfield, Massachusetts (CaymanMama.com) — Two large pharmaceutical companies, Abbott Laboratories and AstraZeneca PLC have partnered up to ask the FDA on Thursday to approve a drug that combines their cholesterol pills TriLipix and Crestor.
Abbott’s TriLipix is a fibrate drug which raises “good” HDL cholesterol, at the same time reducing triglycerides and “bad” LDL cholesterol. AstraZeneca’s Crestor is a statin drug that lowers bad cholesterol and rasies good cholesterol.
According to the Associated Press, “The companies’ application to the FDA seeks approval to treat dyslipidemia, a disorder characterized by elevated cholesterol and triglycerides, a type of fat found in the blood stream. More than 100 million adults in the U.S. have the disorder, according to the American Heart Association.”
If the FDA approves the companies’ request, the drug would be marketed using the brand name Certriad.
Crestor was AstraZeneca’s third best-selling product in 2008 with sales totaling $3.6 billion. Trilipix, launched late last year, had high sales of $253 million in the first quarter, when combined with Tricor.
Abbott Laboratories and AstraZeneca PLC also said that AstraZeneca will start co-promoting Trilipix to doctors in the U.S.
CaymanMama.com - Press Release Distribution Service
Comments
Articles
- Child Custody: A Guide to the Holidays for Separated and Divorced Parents
- Raleigh Divorce Lawyers Create Web Portal with Info on North Carolina Family Law
- Child Support in North Carolina: Part I
- Be Instantly Accessible With The Right Legal Website Design
- Vlogging an Emerging Internet Marketing Trend for Lawyers
- The Importance of a Law Firm’s website URL For SEO
- SEO Maybe the Most Cost Effective Marketing for Lawyers
- Simple Steps for Great Law Firm Internet Marketing
- Weighing SEO and PPC for Law Firm Marketing
- Social Media Marketing Reaches Audience More Effectively




